The interest in glucagon-like petide-1 (GLP-1) and other pre-proglucagon derived peptides
has risen almost exponentially since seminal papers in the early 1990s proposed to use …

Although several classes of pharmacotherapy are available for type 2 diabetes, glycaemic
control is often hampered by medication‐related adverse effects and contraindications such …

In the last few years, a great interest has emerged in investigating the pleiotropic effects of
Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower …

What is known and objective Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are
one of the preferred approved treatment options for people with type 2 diabetes (T2D) and …

Abstract Glucagon-like peptide-1 (GLP-1) is produced in gut endocrine cells and in the
brain, and acts through hormonal and neural pathways to regulate islet function, satiety, and …

Obective Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are indicated for treatment of
type 2 diabetes since they mimic the actions of native GLP‐1 on pancreatic islet cells …

Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus
patients when treated with long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonists …

Objectives: Review the mechanism of action of GLP-1 receptor agonists. Identify the
potential adverse effects of GLP-1 receptor agonists. Outline the methods of administration …

SUMMARY Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists have been shown to
regulate blood glucose concentrations by mechanisms including enhanced insulin …

The glucagon-like peptide (GLP)-1 receptor (GLP-1R) is a class BG protein–coupled
receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three …